Obesity, Non-alcoholic Fatty Liver Disease
Conditions
Brief summary
Changes in VLDL-TG kinetics 8 months after treatment initiation, when their weight loss has stabilized: I) Changes in relation to the degree of weight loss. II) Changes in relation to the amount of fat in the liver, assessed by MRI-PDFF.
Detailed description
Changes between the groups in: I) Hepatic secretion of VLDL-TG particles, II) Glucose kinetics, III) Palmitate kinetics, IV) Circulating lipids, V) Insulin resistance, VI) Inflammatory markers, VII) Gut microbiota and metabolites, VIII) The Fibrosis-4 index (FIB-4), IX) NAFLD fibrosis score (NFS), X) Inflammatory markers in blood, gut, liver, fat, and muscle XI) Histology and gene expression in adipose tissue XII) Muscle mass and muscle structure and in histology and gene expression.
Interventions
Sponsors
Region Midtjylland
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in VLDL-TG kinetics 8 months after treatment initiation, when their weight loss has stabilized: I) Changes in relation to the degree of weight loss. II) Changes in relation to the amount of fat in the liver, assessed by MRI-PDFF. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes between the groups in: I) Hepatic secretion of VLDL-TG particles, II) Glucose kinetics, III) Palmitate kinetics, IV) Circulating lipids, V) Insulin resistance, VI) Inflammatory markers, VII) Gut microbiota and metabolites, VIII) The Fibrosis-4 index (FIB-4), IX) NAFLD fibrosis score (NFS), X) Inflammatory markers in blood, gut, liver, fat, and muscle XI) Histology and gene expression in adipose tissue XII) Muscle mass and muscle structure and in histology and gene expression. | — |
Countries
Denmark
Outcome results
None listed